WO2007051431A3 - Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras - Google Patents

Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras Download PDF

Info

Publication number
WO2007051431A3
WO2007051431A3 PCT/CU2006/000011 CU2006000011W WO2007051431A3 WO 2007051431 A3 WO2007051431 A3 WO 2007051431A3 CU 2006000011 W CU2006000011 W CU 2006000011W WO 2007051431 A3 WO2007051431 A3 WO 2007051431A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferons
alpha
gamma
formulations containing
stable formulations
Prior art date
Application number
PCT/CU2006/000011
Other languages
English (en)
French (fr)
Other versions
WO2007051431A2 (es
Inventor
Rivero Iraldo Bello
Saura Pedro Lopez
Vega Yanelda Garcia
Milian Hector Santana
Barreto Ana Aguilera
Meireles Rolando Paez
Angulo Lorenzo Anasagasti
Original Assignee
Ct Ingenieria Genetica Biotech
Rivero Iraldo Bello
Saura Pedro Lopez
Vega Yanelda Garcia
Milian Hector Santana
Barreto Ana Aguilera
Meireles Rolando Paez
Angulo Lorenzo Anasagasti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Rivero Iraldo Bello, Saura Pedro Lopez, Vega Yanelda Garcia, Milian Hector Santana, Barreto Ana Aguilera, Meireles Rolando Paez, Angulo Lorenzo Anasagasti filed Critical Ct Ingenieria Genetica Biotech
Priority to US12/092,440 priority Critical patent/US8535657B2/en
Priority to JP2008538252A priority patent/JP5366551B2/ja
Priority to EP06805254.7A priority patent/EP1958643B1/en
Priority to CA2629895A priority patent/CA2629895C/en
Priority to KR1020087013121A priority patent/KR101363237B1/ko
Priority to AU2006310918A priority patent/AU2006310918B2/en
Priority to BRPI0618197-0A priority patent/BRPI0618197B1/pt
Priority to ES06805254.7T priority patent/ES2619632T3/es
Publication of WO2007051431A2 publication Critical patent/WO2007051431A2/es
Publication of WO2007051431A3 publication Critical patent/WO2007051431A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está relacionada con formulaciones farmacéuticas estables para ser aplicadas por vía parenteral (líquidas o liofilizadas), o tópica (gel, ungüento o crema) que comprenden diferentes cantidades de los interferones recombinantes gamma y alfa en proporciones potenciadoras para el tratamiento de eventos patológicos que contemplan el crecimiento celular no fisiológico benigno o maligno de tejidos u órganos.
PCT/CU2006/000011 2005-11-02 2006-10-27 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras WO2007051431A2 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/092,440 US8535657B2 (en) 2005-11-02 2006-10-27 Stabilized pharmaceutical formulations that contain the interferons gammas and alpha in synergistic proportions
JP2008538252A JP5366551B2 (ja) 2005-11-02 2006-10-27 相乗的効果を奏する割合でγ−及びα−インターフェロンを含有する安定化製剤
EP06805254.7A EP1958643B1 (en) 2005-11-02 2006-10-27 Stable formulations containing enhancing proportions of gamma- and alpha-interferons
CA2629895A CA2629895C (en) 2005-11-02 2006-10-27 Stable formulations containing enhancing proportions of gamma- and alpha-interferons
KR1020087013121A KR101363237B1 (ko) 2005-11-02 2006-10-27 증강된 비율의 감마 인터페론 및 알파 인터페론을 포함하는안정화된 제형
AU2006310918A AU2006310918B2 (en) 2005-11-02 2006-10-27 Stable formulations containing enhancing proportions of gamma- and alpha-interferons
BRPI0618197-0A BRPI0618197B1 (pt) 2005-11-02 2006-10-27 Formulações farmacêuticas estáveis
ES06805254.7T ES2619632T3 (es) 2005-11-02 2006-10-27 Formulaciones estables que contienen interferones gamma y alfa en proporciones potenciadoras

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2005-0213 2005-11-02
CU20050213A CU23432B6 (es) 2005-11-02 2005-11-02 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Publications (2)

Publication Number Publication Date
WO2007051431A2 WO2007051431A2 (es) 2007-05-10
WO2007051431A3 true WO2007051431A3 (es) 2007-06-28

Family

ID=40269648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2006/000011 WO2007051431A2 (es) 2005-11-02 2006-10-27 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Country Status (15)

Country Link
US (1) US8535657B2 (es)
EP (1) EP1958643B1 (es)
JP (1) JP5366551B2 (es)
KR (1) KR101363237B1 (es)
CN (2) CN104826094A (es)
AR (1) AR056586A1 (es)
AU (1) AU2006310918B2 (es)
BR (1) BRPI0618197B1 (es)
CA (1) CA2629895C (es)
CU (1) CU23432B6 (es)
ES (1) ES2619632T3 (es)
PT (1) PT1958643T (es)
RU (1) RU2403057C2 (es)
WO (1) WO2007051431A2 (es)
ZA (1) ZA200804256B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
ES2389760T3 (es) * 2010-04-14 2012-10-31 B. Braun Melsungen Ag Composición de acetaminofeno
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
CA2989896C (en) 2010-07-22 2021-02-09 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
US20140050724A1 (en) * 2011-04-27 2014-02-20 Northshore University Healthsystem Compositions and Methods
RU2524651C1 (ru) * 2013-06-20 2014-07-27 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме раствора для инъекций и способ ее получения
CN104043110B (zh) * 2014-03-28 2016-05-04 上海交通大学 干扰素温敏水凝胶及其制备方法和应用
EP3485899A4 (en) 2017-09-25 2020-05-20 Georgy Georgievich Chumburidze THERMOSTABLE COMPOSITION HAVING ANTIVIRAL AND ANTIBACTERIAL ACTION, AND USE THEREOF
BR112020011417A2 (pt) * 2017-12-07 2020-11-24 Reven Ip Holdco Llc composições e métodos para o tratamento de condições metabólicas
CA3141418A1 (en) * 2019-06-12 2020-12-17 James Ervin Methods and compositions for improving outcomes of cancer patients
CU20200029A7 (es) * 2020-05-20 2022-01-13 Ct Ingenieria Genetica Biotecnologia Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral
CN114015758B (zh) * 2021-10-15 2022-06-24 无锡百泰克生物技术有限公司 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺
WO2023076813A1 (en) * 2021-10-26 2023-05-04 Georgia State University Research Foundation, Inc. SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法
CN115105584B (zh) * 2022-06-28 2023-03-31 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276120A2 (en) * 1987-01-20 1988-07-27 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5935566A (en) * 1994-10-11 1999-08-10 Schering Corporation Stable aqueous alfa interferon solution formulations
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
WO2004078207A1 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
DE3273597D1 (en) 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
ZA828580B (en) * 1981-12-23 1983-10-26 Schering Corp Interferon formulations
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
ATE52693T1 (de) 1982-10-25 1990-06-15 Genentech Inc Synergistische humaninterferonaktivitaet.
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
FI861193A (fi) * 1985-03-25 1986-09-26 Schering Corp Stabilt gammainterferonpreparat.
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
US5024833A (en) 1988-03-10 1991-06-18 Industrial Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
US5190751A (en) 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US5444064A (en) 1989-02-28 1995-08-22 Montefiore Medical Center Method of treating gastrointestinal malignancies
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
DE69324671D1 (de) 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
CN1163264C (zh) * 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
US5814640A (en) 1994-10-04 1998-09-29 Montefiore Medical Center Method of treating gastrointestinal malignancies
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003014112A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Cristal et procede de fabrication correspondant
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
JP2006509825A (ja) * 2002-12-13 2006-03-23 大塚製薬株式会社 経肺投与用インターフェロン−γ凍結乾燥組成物及びその吸入システム
JP2005162663A (ja) * 2003-12-02 2005-06-23 Asahi Denka Kogyo Kk 皮膚用基剤
US20050123575A1 (en) * 2003-12-03 2005-06-09 Eilon Asculai Spreadable compositions for topical use, an improved process of making same and methods of using same
EP2102748B1 (en) * 2006-12-22 2012-02-01 International Business Machines Corporation System and method for recovery of memory transactions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276120A2 (en) * 1987-01-20 1988-07-27 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5935566A (en) * 1994-10-11 1999-08-10 Schering Corporation Stable aqueous alfa interferon solution formulations
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
WO2004078207A1 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989, ISHII Y ET AL: "THE SYNERGISTIC EFFECT OF HUMAN RECOMBINANT INTERFERON-ALPHA-2-ALPHA IN COMBINATION WITH INTERFERON-GAMMA AND THE INDUCTION OF INTERFERON-ALPHA-2-ALPHA RECEPTOR BY INTERFERON-GAMMA", XP002427340, Database accession no. PREV198988087423 *
JOURNAL OF PHARMACOBIO-DYNAMICS, vol. 12, no. 5, 1989, pages 299 - 304, ISSN: 0386-846X *
SCHWAAB T ET AL: "A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon [gamma] and human recombinant interferon [alpha]2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters", JOURNAL OF UROLOGY 2000 UNITED STATES, vol. 163, no. 4, 2000, pages 1322 - 1327, XP005555804, ISSN: 0022-5347 *

Also Published As

Publication number Publication date
ZA200804256B (en) 2009-05-27
BRPI0618197A2 (pt) 2013-01-08
PT1958643T (pt) 2017-03-23
JP2009513682A (ja) 2009-04-02
EP1958643B1 (en) 2016-12-28
RU2008121874A (ru) 2009-12-10
CN104826094A (zh) 2015-08-12
US20090304628A1 (en) 2009-12-10
KR20080065684A (ko) 2008-07-14
CU23432B6 (es) 2009-10-16
AU2006310918A1 (en) 2007-05-10
CN101351219A (zh) 2009-01-21
ES2619632T3 (es) 2017-06-26
RU2403057C2 (ru) 2010-11-10
CA2629895A1 (en) 2007-05-10
AU2006310918B2 (en) 2012-09-27
US8535657B2 (en) 2013-09-17
WO2007051431A2 (es) 2007-05-10
CA2629895C (en) 2016-08-30
EP1958643A2 (en) 2008-08-20
JP5366551B2 (ja) 2013-12-11
AR056586A1 (es) 2007-10-10
BRPI0618197B1 (pt) 2021-06-29
KR101363237B1 (ko) 2014-02-12

Similar Documents

Publication Publication Date Title
WO2007051431A3 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2002059377A3 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
EP1329458A3 (en) Peptides that lower blood glucose levels
WO2004101758A3 (en) Composition for maintaining organ and cell viability
TW200605870A (en) Topical methadone compositions and methods for using the same
TW200744661A (en) Topical cosmetic formulations for regulating and improving the moisture content of the skin
WO2006087759A3 (en) Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
WO2006094193A3 (en) Compositions and methods for topical application and transdermal delivery of an oligopeptide
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone
WO2006010070A3 (en) Compositions and methods related to peptides that selectively bind leukemia cells
WO2003038060A3 (en) Small molecule inhibitors targeted at bcl-2
WO2004091497A3 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
WO2007017176A8 (en) Wound-healing composition
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2006137100A3 (en) Molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives thereof and related uses in medical field
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2007025166A3 (en) Devices, compositions and methods for the protection and repair of cells and tissues
WO2007034042A3 (fr) Extrait de vanilla planifolia, son procede d’obtention, et composition cosmetique ou dermatologique le contenant
WO2010051320A3 (en) Methods for assembling panels of cancer cell lines for use in testing the efficacy of one or more pharmaceutical compositions
WO2003106384A3 (en) NOVEL BORIC CHALCONE DERIVATIVES AND USES THEREOF
WO2003053180A3 (de) Wirkstoffhaltige unterwäsche
WO2007050369A3 (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2005063195A3 (en) Compositions comprising vitamins and/or derivatives thereof stabilised with olea europea extract and/or ionene polymers
EP1236465A3 (en) Use of legume products for the treatment of external aggressions

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008538252

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005863

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3985/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2629895

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006310918

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087013121

Country of ref document: KR

REEP Request for entry into the european phase

Ref document number: 2006805254

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006805254

Country of ref document: EP

Ref document number: 2008121874

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006310918

Country of ref document: AU

Date of ref document: 20061027

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006310918

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680050242.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006805254

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12092440

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0618197

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080502